ArticleJournal of physiology and biochemistry2011
Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin.
Article in Journal of physiology and biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Integrating machine learning and bioinformatics approaches to identify novel diagnostic gene biomarkers for diabetic mice.Scientific reports · 2025Article
- Article
- Does diabetes mellitus affect the safety profile of valproic acid for the treatment of status epilepticus? A retrospective cohort study.Neurological research and practice · 2022Article
- Maternal stress induced endoplasmic reticulum stress and impaired pancreatic islets' insulin secretion via glucocorticoid receptor upregulation in adult male rat offspring.Scientific reports · 2022Article
- Wolframin is a novel regulator of tau pathology and neurodegeneration.Acta neuropathologica · 2022Article
- The Expression of RAAS Key Receptors,Genes · 2021Article
- A mutant wfs1 zebrafish model of Wolfram syndrome manifesting visual dysfunction and developmental delay.Scientific reports · 2021Article
- Collaboration for rare diabetes: understanding new treatment options for Wolfram syndrome.Endocrine · 2021Review
- Wolfram Syndrome: a Monogenic Model to Study Diabetes Mellitus and Neurodegeneration.Current opinion in physiology · 2020Article
- Effect of 4-phenylbutyrate and valproate on dominant mutations of WFS1 gene in Wolfram syndrome.Journal of endocrinological investigation · 2020Article
- A cost of illness study evaluating the burden of Wolfram syndrome in the United Kingdom.Orphanet journal of rare diseases · 2019Article
- Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.Scientific reports · 2018Article
- Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration.Scientific reports · 2017Article
- Does Valproic Acid Have Potential in the Treatment of Diabetes Mellitus?Frontiers in endocrinology · 2017Article
- RNA-sequencing of WFS1-deficient pancreatic islets.Physiological reports · 2016Article
- Prohormone convertase 2 activity is increased in the hippocampus of Wfs1 knockout mice.Frontiers in molecular neuroscience · 2015Article
- Effect of chronic valproic Acid treatment on hepatic gene expression profile in wfs1 knockout mouse.PPAR research · 2014Article
- Meeting report of the European mouse complex genetics network SYSGENET.Mammalian genome : official journal of the International Mammalian Genome Society · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valproic acid (VLP) is a widely used anticonvulsant and mood-stabilizing drug that relieves the endoplasmic reticulum (ER) stress response, a pathogenetic process related to diabetes. The aim of the present study was to evaluate whether acute valproic acid is able to interfere with glucose intolerance in two different diabetes models: The first model was a Wfs1 mutant mouse with an elevated ER stress response and the second model a streptozocin-induced diabetic mouse. VLP (300 mg/kg, i.p.) was administered to Wfs1 knockout (KO) mice and glucose tolerance test was performed 15 min later. VLP did not have an effect on the course of the glucose tolerance test in wild-type mice, while it did normalize the glucose intolerance in Wfs1 knockout mice. Acute valproic acid also lowered the blood glucose levels in streptozocin-treated mice and potentiated the effect of insulin in these mice. Thus, acute valproic acid is effective in lowering blood glucose levels possibly by potentiating insulin action in both Wfs1 KO mice and in streptozocin-induced type 1 diabetic mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.